Actually, sildenafil is not specific to any of these two conditions and targets a number of the 57 pathways in common between type 1 diabetes and multiple sclerosis including but not limited to pathways mentioned in Table 2, such as “IL-3, 5 and GM CSF signaling” (z=−1.6), “regulation of signaling by CBL” (z=−1.1), “regulation of KIT signaling” (z=−1.0), “IL receptor SHC signaling” (z=−1.0), and “growth hormone receptor signaling” (z=−1.0). This evidence concerns the gene KIT and type 1 diabetes mellitus.